@FiercePharma: GSK's new respiratory launches will give its revamped sales model a workout - FP. Story | Follow @FiercePharma
@TracyStaton: ICYMI: Thumbs up or down on megamergers? Depends on your point of view. More | Follow @TracyStaton
@EricPFierce: No sooner does Commish Hamburg return from India than the FDA reveals a new warning letter about data faking there. News | Follow @EricPFierce
@CarlyHFierce: Yesterday's best-read on FP: Activists urge FDA to slap black-box warnings on lucrative testosterone boosters. Article | Follow @CarlyHFierce
> A coalition of healthcare, consumer and addiction treatment groups is pressing the FDA to revoke its approval of opioid painkiller Zohydro, which lacks abuse-deterrent characteristics. Story
> A second University, UC Santa Barbara, is now using Novartis' ($NVS) meningitis B vaccine to protect students and staff after an outbreak. More
> The FDA has approved AstraZeneca's ($AZN) Myalept to treat a rare metabolic disease. Release
> The U.K.'s cost watchdog has backed a new use for Bayer's Eylea, publishing final guidance that recommends the drug for use in macular edema patients. News
> Bayer said it will propose a dividend of €2.10 ($2.90) to investors, topping the €2.07 expected by analysts. Report
> Belgian pharma UCB saw revenue fall in 2013, but it expects that to turn around this year. Report
@FierceMedDev: Foundation Medicine ended its first (partial) year as a public company revenue still heading higher. Release | Follow @FierceMedDev
@MarkHFierce: In the (marathon) battle to overturn the device tax, word from a pediatric device company CEO might help. More | Follow @MarkHFierce
@MichaelGFierce: FDA panel moves to ease iontophoresis delivery regulations to reflect modern advances. News | Follow @MichaelGFierce
@EmilyWFierce: Seno Medical Instruments raises $39M in a critical funding round for breast cancer dx device. More | Follow @EmilyWFierce
@GalenMoore: FDA may have gone too far, reading personal emails of medtech approval whistleblowers. Story | Follow @GalenMoore
> Qiagen has unveiled a low-tech HPV test in India. Piece
> A pediatric device company CEO speaks out against the device tax. More
Biotech News
@FierceBiotech: Novartis takes the transparency 'pledge,' but is it too little, too late? More | Follow @FierceBiotech
@JohnCFierce: Are Lily and J&J on the short list? Mystery U.S. pharma company circles Andromeda and its PhIII diabetes drug. Story | Follow @JohnCFierce
@DamianFierce: With a reported $330M+ on the way, Abingworth is the latest biotech VC amassing a new fund. News | Follow @DamianFierce
@EmilyMFierce: Trending at FierceBiotechResearch.com --> Scientist: Let's not discredit acid-bath stem cell studies--yet. More | Follow @EmilyMFierce
> Anika pops after the FDA finally approves its arthritis jab. Article
> Northwest Bio shoots for dendritic success where others have failed. Story
Diagnostics News
> Daktari Diagnostics is raising up to $30M to support its Africa HIV test launch. Story
> Loyola team zeros in on an early-stage heart attack biomarker. Research
> Diagnostic Biochips is pursuing angel funding for a microchip brain implant. News
> A massive review reaffirms fecal test's place in colon cancer Dx. Article
> Tumor DNA can serve as noninvasive biomarker to stage and help treat cancer. Article
> Ezose Sciences will explore glycans as a possible Parkinson's biomarker. Brief
Drug Delivery News
> Clustered nanoparticles deliver chemo to fight drug-resistant ovarian cancer. News
> Inner-ear delivery device sends drugs out, draws fluid in. More
> FDA panel moves to ease iontophoresis delivery regulations to reflect modern advances. Story
> Teva snags an EU recommendation for its asthma, COPD inhaler. Article
> Single microparticle holds 3 different drugs for a cancer 1-2-3 punch. Piece
> Nanoparticles deliver chemotherapy when hit with a targeted light. Item
Pharma Marketing News
> Lilly's dulaglutide matches Victoza in study, but the real loser is AstraZeneca's Bydureon. Analysis
> Endo's off-label Lidoderm mantra, whistleblower says: 'Put the patch where the pain is.' Story
> GSK's new respiratory launches will give its revamped sales model a workout. News
> Even for busy doctors, 'nothing is as good as a rep' for getting pharma info. Article
> Amarin's future dims further as FDA nixes 5-year Vascepa exclusivity. Story
> Eisai's revved-up Belviq marketing starting to pay off, analysts say. Story
> Thrombogenics is 'exploring options' to jump-start Jetrea sales. Marketing partner, perhaps? Brief
And Finally... A new analysis says that despite the falling number of new cases of bladder cancer in England, survival of the disease is worsening. More